Venous thromboembolic disease: Clinical practice guidelines in Oncology™

Lawrence D. Wagman, Melissa F. Baird, Charles L. Bennett, Paula L. Bockenstedt, Spero R. Cataland, John Fanikos, Patrick F. Fogarty, Samuel Z. Goldhaber, Tejpal S. Grover, William Haire, Hani Hassoun, Mohammad Jahanzeb, Lawrence L. Leung, Michael L. Linenberger, Michael M. Millenson, Thomas L. Ortel, Riad Salem, Judy L. Smith, Michael B. Streiff

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


Recognizing the increased risk of VTE in cancer patients is the first step in preventing the occurrence of VTE and promptly identifying the disease in cancer patients. The NCCN panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who do not have contraindications to such therapy, and the panel also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. Careful evaluation and follow-up of cancer patients in whom VTE is suspected and prompt treatment and follow-up for patients diagnosed with VTE is recommended after the cancer status of the patient and the risks and benefits of treatment are considered.

Original languageEnglish (US)
Pages (from-to)838-869
Number of pages32
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number9
StatePublished - Oct 2006


  • Anticoagulation
  • Cancer
  • Deep venous thrombosis
  • Heparin
  • NCCN Clinical Practice Guidelines
  • Pulmonary embolism
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Venous thromboembolic disease: Clinical practice guidelines in Oncology™'. Together they form a unique fingerprint.

Cite this